Ascentage Pharma Group International
HKEX:6855
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.7
47.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Ascentage Pharma Group International stock under the Base Case scenario is 58.18 HKD. Compared to the current market price of 41.3 HKD, Ascentage Pharma Group International is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Ascentage Pharma Group International
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
Historical valuation for Ascentage Pharma Group International cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ascentage Pharma Group International
Balance Sheet Decomposition
Ascentage Pharma Group International
Current Assets | 2B |
Cash & Short-Term Investments | 1.1B |
Receivables | 743.5m |
Other Current Assets | 120m |
Non-Current Assets | 1.1B |
Long-Term Investments | 33.2m |
PP&E | 931.2m |
Intangibles | 104.5m |
Other Non-Current Assets | 74.4m |
Current Liabilities | 1.1B |
Accounts Payable | 83.1m |
Short-Term Debt | 120m |
Other Current Liabilities | 862.3m |
Non-Current Liabilities | 1.3B |
Long-Term Debt | 970.6m |
Other Non-Current Liabilities | 304.8m |
Earnings Waterfall
Ascentage Pharma Group International
Revenue
|
903m
CNY
|
Cost of Revenue
|
-27.4m
CNY
|
Gross Profit
|
875.6m
CNY
|
Operating Expenses
|
-1.2B
CNY
|
Operating Income
|
-329.9m
CNY
|
Other Expenses
|
-30.4m
CNY
|
Net Income
|
-360.3m
CNY
|
Free Cash Flow Analysis
Ascentage Pharma Group International
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Ascentage Pharma Group International's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Ascentage Pharma Group International's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Ascentage Pharma Group International's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Ascentage Pharma Group International's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Ascentage Pharma Group International
According to Wall Street analysts, the average 1-year price target for Ascentage Pharma Group International is 48.96 HKD with a low forecast of 41.41 HKD and a high forecast of 57.75 HKD.
Dividends
Current shareholder yield for Ascentage Pharma Group International is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ascentage Pharma Group International Co., Ltd. develops and produces pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 613 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one Ascentage Pharma Group International stock under the Base Case scenario is 58.18 HKD.
Compared to the current market price of 41.3 HKD, Ascentage Pharma Group International is Undervalued by 29%.